Anual financial news and ad hoc releases

Anual financial news and ad hoc releases

In our archive you will find financial news since 2005

05.05.2017

MediClin could increase Group sales by 3.7 % in the first quarter of 2017 compared to the first quarter 2016

Offenburg, 5 May 2017 – In the first quarter of 2017 MEDICLIN Aktiengesellschaft (MediClin) achieved Group sales of EUR 147.1 mill., EUR 5.2 mill. or 3.7% up against the figure of the first quarter 2016. The Group EBIT of the comparable quarter 2016 was not achieved, mainly due to higher staff costs (EUR +5.2 mill.). The Group-EBIT was EUR -0.5 mill. (Q1 2016: EUR 1.7 mill.).

The financial result was moderately better at EUR -0.5 mill., total consolidated result attributable to shareholders of MEDICLIN Aktiengesellschaft was EUR -0.8 mill. (Q1 2016: EUR 0.9 mill.). Earnings per share came to EUR -0.02 (Q1 2016: EUR 0.02).

Sales in the post-acute segment amounted to EUR 88.1 mill. and were EUR 4.4 mill. or 5.3 % higher than in the same period of the previous year. Based on indications a higher occupancy especially in neurology, acute neurology, geriatrics and orthopaedics contributed to sales growth. The positive sales development of the segment is also founded on the ability that MediClin could recruit qualified staff despite skills shortage in the healthcare market. Sales in the acute segment accounts for EUR 54,3 mill. and increased moderately by EUR 0.6 mill. Sales in the nursing care business area rose by EUR 0.2 mill. up to EUR 3.8 mill.

In the post-acute segment the segment result (EUR 0.7 mill.) could be improved due to a disproportionately low increase in raw materials and consumables used compared to sales growth despite increased staff costs because of a higher number of employees (+ 112 full-time employees). In the acute segment, an increase in raw materials and consumables used and, in particular, higher staff costs also due to a higher number of employees (+ 81 full-time employees) meant that the segment result (EUR −0.9 mill.) came in below the previous year’s figure.

In the first quarter of 2017, the development of the post-acute segment is in line with the guidance. Regarding the forecast for the acute segment, it is to be seen what effect the introduced measures will have in the coming months.

Gross investments amounted to EUR 11.2 mill. in the first quarter of the 2017 financial year (Q1 2016: EUR 7.1 mill.), pertaining mainly to the reconstruction and expansion of clinics and the acquisition of medical equipment. Capital expenditure is thus in line with the annual budget. Cash and cash equivalents as of 31 March 2017 amounted to EUR 31.0 mill. (31.12.2016: EUR 41.6 mill.).

 
The interim report as of 31 March 2017 is available on the homepage of MediClin in German and English. www.mediclin.de

About MediClin AG (Ticker: MED; WKN: 659 510)
MediClin AG is a nation-wide clinic operator and large provider of services in the area of Psycho- and Neurosciences as well as Orthopaedic. With 34 clinics, 7 nursing care facilities and 8 medical care centres in 11 federal states MediClin has a total capacity of close to 8,100 beds. MediClins’ facilities include acute care clinics, general hospitals, special treatment facilities, specialised hospitals and clinics for post-acute treatment as well as medical rehabilitation. MediClin has approximately 9,300 employees.

Important notice:
This press release includes future-oriented statements which are based on assumptions and estimates. While MediClin AG is of the opinion that these assumptions and estimates are correct, the actual future developments and actual future results may deviate from these assumptions and estimates due to the impact of various factors such as changes in the economic conditions in Germany, legal changes concerning the health system, changes relating to cost providers’ expense behaviour. MediClin does not assume liability and gives no warranty that future developments and the income actually achieved in the future will comply with the assumptions and estimates stated in this press release.